SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Suvaxyn MH-One emulsion for injection for pigs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 2 ml dose contains:

Active substance:

Inactivated *Mycoplasma hyopneumoniae*, strain P-5722-3	RP* (undiluted) ≥ 1.00

Adjuvants:

Carbopol #941	4.00 mg
Squalane**	3.24 mg

*Relative Potency unit determined by ELISA antigen quantification (*in vitro* potency test) compared to a reference vaccine.
**As component of MetaStim (that also contains Pluronic L-121 and Polysorbate 80).

Excipients:

Thiomersal	0.20 mg

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Brownish-grey emulsion.

4. CLINICAL PARTICULARS

4.1 Target species

Pigs.

4.2 Indications for use, specifying the target species

For active immunisation of pigs of a minimum age of 7 days to reduce lung lesions that are caused by *Mycoplasma hyopneumoniae.*

Onset of immunity: 2 weeks.
Duration of immunity: 6 months after vaccination.

4.3 Contraindications

None.

4.4 Special warnings for each target species

Vaccinate healthy animals only.

4.5 Special precautions for use

Special precautions for use in animals
Avoid stress in the animals around the time of vaccination.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
This veterinary medicinal product contains animal oil. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment
Not applicable.

Other precautions
Not applicable.

4.6 Adverse reactions (frequency and seriousness)

Pigs:

Very common (>1 animal / 10 animals treated):	Injection site swelling[1] Shivering[2] Piloerection[2] Depression[2], Elevated temperature[2/3]
Uncommon (1 to 10 animals / 1,000 animals treated):	Anaphylactic-type reaction Neurological signs

[1]May reach 0.3 cm in diameter (palpable, but not visible) and last for up to 2 days.
[2]Within 4 hours after vaccination and spontaneously resolving within 24 hours without treatment.
[3]Body temperature increase up to 1.9°C.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also section 16 of the package leaflet for contact details.

4.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:
Do not use in pregnant or lactating animals.

4.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9 Amount(s) to be administered and administration route

One dose (2 ml) per animal should be administered intramuscularly in the neck to pigs from the age of 7 days onwards.

Shake vaccine well before administration and intermittently during the process of vaccination.

It is good practice to allow the vaccine to warm to body temperature in the hand or pocket before administration, to avoid the discomfort of injection of a cold liquid.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

After administration of a two-fold overdose by the recommended route to 3 weeks-old pigs, no other symptoms than those described under section 4.6 “Adverse reactions” can be observed. However, the duration may be prolonged (body temperature increases up to 2 days and local tissue reactions up to 3 days) and the area of local tissue reactions may reach 1.0 cm in diameter. Administration of an overdose of the vaccine has not been investigated in 1 week-old piglets.

4.11 Withdrawal period(s)

Zero days.

5. IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: Inactivated bacterial vaccines – pigs.

ATCvet code: QI09AB13

To stimulate active immunity against *Mycoplasma hyopneumoniae.*
Post-vaccination serum antibody levels are not related to the degree of protection afforded by vaccination.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Thiomersal
Sodium chloride
Potassium chloride
Sodium phosphate dibasic x12 H_2O
Potassium phosphate monobasic
Polysorbate 80
Pluronic L-121
EDTA Tetrasodium $2H_2O$
Sodium Borate
Sodium Phosphate Dibasic
Water for injections

6.2 Major incompatibilities

Do not mix with any other veterinary medicinal product.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after first opening the immediate packaging: use immediately.

6.4 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Store in the original container.
Protect from light.

6.5 Nature and composition of immediate packaging

Container: HDPE bottle.

Filling volume:125 doses (250 ml), 50 doses (100 ml), 10 doses (20 ml) of vaccine.

Closure: butyl rubber stopper with aluminium cap.

Packaging: carton box containing 1 or 10 bottles of 10, 50 or 125 doses.

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey
KT22 7LP

8. MARKETING AUTHORISATION NUMBER

Vm 42058/5123

9. DATE OF FIRST AUTHORISATION

24 October 2008

10. DATE OF REVISION OF THE TEXT

May 2024

11. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' or 'PID' on www.gov.uk.

Approved 18 May 2024
Gavin Hall